8-K: OS Therapies Finalizes Acquisition of Ayala Pharmaceuticals' Immunotherapy Assets, Bolstering Cancer Pipeline

OS Therapies completes the acquisition of Ayala Pharmaceuticals' listeria-based cancer immunotherapy assets, expanding its clinical pipeline and solidifying its position as a leader in the field.

Summary

• OS Therapies has completed the acquisition of the listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals on April 9, 2025.
• The acquired assets include two Investigational New Drug filings with the FDA: ADXS-503 for Non-Small Cell Lung Cancer and ADXS-504 for Prostate Cancer.
• The acquisition involved the elimination of $20 million in milestone payments owed to Ayala and a reduction in royalty consideration from 10% to 1.5% of net sales, payable to the University of Pennsylvania.
• The purchase price was $8 million, paid through a combination of cash ($500,000) and OS Therapies common stock (4,774,637 shares).
• Due to NYSE ownership limitations, OS Therapies initially issued 2,164,215 shares and a warrant to purchase 2,166,381 shares.
• The company will seek stockholder approval to issue the remaining 444,041 shares or a warrant for the same amount.
• Ayala has agreed to a 180-day lock-up period on the Consideration Shares.
• OS Therapies intends to submit a BLA Accelerated Approval request to the US FDA in the third quarter of 2025 for OST-HER2.
• Upon approval of OST-HER2, the Company will become eligible to receive a Priority Review Voucher, currently valued at $150 million.
• The global cancer immunotherapy market size was valued at $126 billion in 2023 and is projected to surpass around $296 billion by 2033.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the acquisition's strategic benefits, pipeline expansion, and potential for future growth. However, the stock dilution and regulatory risks temper the overall sentiment.

Positives

• OS Therapies has expanded its pipeline with clinical and pre-clinical cancer immunotherapy programs.
• The company has consolidated intellectual property for the listeria cancer immunotherapy platform.
• The acquisition eliminates $20 million in milestone payments owed to Ayala.
• The company is targeting a BLA submission for OST-HER2 in Q3 2025, with potential for a $150 million Priority Review Voucher.
• The company now has late-stage, mid-stage and early-stage cancer immunotherapy candidates, a rich pipeline of preclinical cancer immunotherapy candidates and a long IP runway to in order to fully leverage this powerful cancer immunotherapy platform.

Negatives

• The acquisition involved the issuance of a significant number of shares, potentially diluting existing shareholders.
• The issuance of additional shares is contingent upon stockholder approval.
• The company is dependent on FDA approval for OST-HER2 and the receipt of the Priority Review Voucher.

Risks

• The company faces risks associated with the development and regulatory approval of its immunotherapy candidates.
• The company's success depends on the successful commercialization of OST-HER2 and other pipeline assets.
• The company is subject to risks related to competition in the cancer immunotherapy market.
• The company is subject to risks related to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in the Company's registration statement on Form S-1 filed with the Securities and Exchange Commission (the SEC) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q.

Future Outlook

OS Therapies aims to become a leader in listeria-based cancer immunotherapies and plans to submit a BLA for OST-HER2 in Q3 2025. The company anticipates potential approval and a Priority Review Voucher, while also focusing on expanding its pipeline and leveraging its immunotherapy platform.

Management Comments

• Paul Romness, CEO of OS Therapies, stated that the acquisition positions the company to fully expand the listeria cancer immunotherapy platform and improve the standard of care across cancer treatment.
• Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies, believes the listeria cancer immunotherapy platform holds tremendous potential to improve outcomes for cancer patients worldwide.

Industry Context

The acquisition aligns with the growing trend of immunotherapy in cancer treatment. The global cancer immunotherapy market is projected to reach $296 billion by 2033, indicating significant growth potential for companies like OS Therapies.

Comparison to Industry Standards

• The acquisition of Ayala's listeria-based immunotherapy assets positions OS Therapies to compete with companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) in the broader immunotherapy market.
• The potential $150 million Priority Review Voucher is a significant asset, comparable to those obtained by other companies developing therapies for rare pediatric diseases.
• The focus on listeria-based immunotherapy provides a unique approach compared to more common immune checkpoint inhibitors, potentially offering advantages in specific cancer types.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's growth and expanded pipeline.
• Cancer patients may benefit from the development of new immunotherapy treatments.
• Suppliers and partners may see increased business opportunities with OS Therapies.

Next Steps

• Obtain stockholder approval for the issuance of additional shares.
• File one or more registration statements to register the resale of the Consideration Shares.
• Submit a BLA Accelerated Approval request to the US FDA for OST-HER2 in the third quarter of 2025.
• Advance the development of other clinical and pre-clinical immunotherapy programs.

Key Dates

Keywords

immunotherapy, cancer, acquisition, OST-HER2, Ayala Pharmaceuticals, listeria, clinical trial, FDA, priority review voucher, oncology